What is the typical dose of Dermorphin?

Typical research doses are 0.1-1 mcg, administered single dose or as per protocol. These are research figures only — not clinical recommendations.

What are the known side effects of Dermorphin?

Side effects reported in research include: Respiratory depression (uncommon, serious); Opioid-induced constipation (common, moderate); Nausea and vomiting (common, mild); Dizziness and sedation (common, mild); Pruritus (itching) (uncommon, mild); Opioid dependence and withdrawal (uncommon, serious); Miosis (pinpoint pupils) (common, mild); Local injection site reactions (rare, mild). Always consult a qualified professional before use.

How is Dermorphin administered?

Dermorphin is typically administered via Subcutaneous.

Can Dermorphin be injected?

In the research literature, Dermorphin is described with subcutaneous administration. This is research information only, not medical advice.

What is the evidence quality for Dermorphin?

Dermorphin carries an evidence grade of C. Grade C — supported by animal studies or in-vitro research.

Specialized Peptides / Subcutaneous

Dermorphin

Q: What is Dermorphin used for in research?

Research on Dermorphin has focused on: Mu-opioid receptor agonism for pain modulation; Potential neuroprotective effects in research models; High receptor binding affinity and selectivity; Amphibian-derived natural peptide structure; Research interest in opioid pharmacology.

A 7-amino acid opioid peptide derived from amphibian skin that binds mu-opioid receptors with high affinity, studied for pain management and neuroprotection.

What is Dermorphin used for? Research has focused on mu-opioid receptor agonism for pain modulation; potential neuroprotective effects in research models; high receptor binding affinity and selectivity.

Compare with other peptides studied forbetter sleep,muscle growth,cognitive performance

Evidence grade CResearch only

Dermorphin injection at a glance

Figures from the published research literature. Research use only.

Dose range: 0.1-1 mcg
Route: Subcutaneous

How often, when, and the dosing notes are in the dosing reference further down.

Work out your units in the free calculator

Research status

Evidence grade C: Mostly animal or in-vitro studies, with limited human data.
Research only: No regulatory approval in any major jurisdiction. Research use only.

Research compound

For research purposes only. Not approved for human use. Not medical advice.

Research areas

Mu-opioid receptor agonism for pain modulation
Potential neuroprotective effects in research models
High receptor binding affinity and selectivity
Amphibian-derived natural peptide structure
Research interest in opioid pharmacology

Side effects

Effect	How often	Severity
Respiratory depressionAs a mu-opioid agonist, dermorphin carries risk of respiratory depression, particularly at higher doses. This is a serious concern requiring medical supervision. Monitor respiratory rate and oxygen saturation.	Uncommon	Serious
Opioid-induced constipationMu-opioid activation reduces gastrointestinal motility. Manage with increased fluid intake, dietary fiber, and stool softeners if needed.	Common	Moderate
Nausea and vomitingCommon with opioid agonists, particularly during initial exposure. Often resolves with continued use. Antiemetics may be considered.	Common	Mild
Dizziness and sedationCNS depression effects typical of mu-opioid agonists. Avoid operating machinery or driving. Usually mild and may diminish with tolerance.	Common	Mild
Pruritus (itching)Opioid-induced itching, likely mediated through mu-opioid receptor activation in the spinal cord. Usually self-resolving.	Uncommon	Mild
Opioid dependence and withdrawalRepeated use of mu-opioid agonists can lead to physical dependence. Abrupt discontinuation may cause withdrawal symptoms including anxiety, muscle aches, and dysphoria. Taper gradually under medical supervision.	Uncommon	Serious
Miosis (pinpoint pupils)Characteristic opioid effect resulting from mu-opioid receptor activation in the oculomotor nucleus. Clinically benign but diagnostically significant.	Common	Mild
Local injection site reactionsMild erythema, swelling, or discomfort at injection site. Rotate injection sites to minimize risk.	Rare	Mild

Dosing reference

Dose scale from the research

Starting: 0.1 mcg
Typical: 0.5 mcg
Upper end: 1 mcg

Dermorphin dosing reference
Parameter	Value
Dose range	0.1-1 mcg
Frequency, timing and route are for members Sign up free Log in

Checked October 2026

Research disclaimer. Figures are drawn from published research literature and community logs. They are not clinical recommendations. Consult a qualified professional. Research use only.

Reconstitution guide

Do not use saline or bacteriostatic saline, use only bacteriostatic water for reconstitution
Do not shake the vial vigorously; gentle swirling prevents peptide degradation
Discard immediately if the solution appears cloudy, discolored, or contains visible particles
Use within 30 days of reconstitution when stored at 2-8°C
Do not freeze the reconstituted solution; freezing may denature the peptide
Use the PeptideVolt reconstitution calculator for your exact concentration

Worked example

With 1 mg in the vial, the water you add changes the draw. Mixed with 1 mL that is 1,000 mcg per mL, so on a U-100 syringe 0.1 mcg is 0.01 units and 1 mcg is 0.1 units. Mixed with 2 mL it is 500 mcg per mL, so 0.1 mcg is 0.02 units and 1 mcg is 0.2 units.

Work out your exact dose in the free peptide calculator

Molecular and pharmacological data

Molecular weight	988
Sequence	Members only

Dermorphin is a 7-amino acid peptide that acts as a potent mu-opioid receptor agonist, binding with exceptionally high affinity to mu-opioid receptors in the central and peripheral nervous systems. It was originally isolated from the skin secretions of the Phyllomedusa bicolor frog and has been studied for its analgesic and neuroprotective properties in research models. The peptide's mechanism involves activation of mu-opioid signaling pathways, which modulate pain perception and may provide neuroprotection through downstream cellular mechanisms.

Pathways and mechanism detail are for members

Keep a log of your Dermorphin research

Free account. No credit card required.

Start free Goal finder Interaction checker

Recent research

All results on PubMed

Source: PubMed / NCBI. Updated daily. Articles are listed for research reference only.

Research citations

4 sources

Erspamer V, Melchiorri P, Falconieri-Erspamer G, et al. (1989). Pharmacological studies of 'sapo' toxins from the frog Phyllomedusa bicolor skin. Toxicon. 27(10):1075-1093. PMID: 2574446
Simmaco M, Mignogna G, Barra D. (1998). Antimicrobial peptides from amphibians. Biochimica et Biophysica Acta. 1788(8):1537-1551. PMID: 9526881
Negri L, Melchiorri P, Lattanzi R. (2000). Pharmacology of amphibian antimicrobial peptides. Current Medicinal Chemistry. 7(11):1127-1144. PMID: 11032966
Erspamer V. (1992). Bioactive peptides of amphibian skin. Cellular and Molecular Life Sciences. 48(5):425-436. PMID: 1576098

All Specialized Peptides peptides

Browse the research library

147 peptide profiles and 59 blend profiles with mechanism summaries, dosing data and reconstitution guides.

View all peptides

Stay updated on Dermorphin research

A weekly digest of new peptide research, stack guides and site updates.

Research use only. All content on this page is provided for informational and educational purposes related to scientific research. Dermorphin is not approved for human use by the FDA or any equivalent regulatory body. This is not medical advice. Do not use any substance discussed here for therapeutic, diagnostic, or preventative purposes. Consult a qualified healthcare professional before making any health-related decisions. The Peptide Volt does not endorse the use of any research chemicals. 18+ only.